KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. Takenaka K, Minami T, Yoshihashi Y, Hirata S, Kimura Y, Kono H.

    Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.

    Allergol Int.2019 Oct;68(4):539-540. doi: 10.1016/j.alit.2019.04.006. Epub 2019 May 9. PMID: 31080020

  2. Shirayama R, Takedani H, Chikasawa Y, Ishiguro A, Ishimura M, Isobe K, Uchiba M, Ogata Y, Kakuda H, Kusuhara K, Shirahata A.

    Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.

    Blood Coagul Fibrinolysis.2019 Dec;30(8):385-392. doi: 10.1097/MBC.0000000000000851. PMID: 31738288

  3. Murata S, Mushino T, Hosoi H, Kuriyama K, Nishikawa A, Nagakura S, Horikawa K, Yonemura Y, Nakakuma H, Sonoki T, Hanaoka N.

    Soluble NKG2D ligands are potential biomarkers and sentinels of  immune-mediated bone marrow injury in bone marrow failure syndromes.

    Acta Haematol.2020;143(1):33-39.  doi: 10.1159/000500657. Epub 2019 Jun 19. PMID: 31216534

  4. Ikebe E, Matsuoka S, Tanaka A, Yonemura Y, Fujii Y, Ohsaka A, Okazaki H, Kitazawa J, Ohtani S, Nakayama T, Momose S, Miwa I, Taira R, Yoyota K, Kino S, Kato H, Hamaguchi I.

    Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan- A retrospective multicenter study.

    Transfusion and Apheresis Science .2019 Apr;58(2):162-168.  PMID: 30670326

  5. Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C.

    JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM)

    International Journal of Hematolog. 2019 May;109(5):509-538. doi: 10.1007/s12185-019-02636-8. Epub 2019 Apr 4. PMID: 30949913

  6. Nishimura N, Endo S, Kawano Y,

    Myeloma Mouse Models in Studying Myeloma Associated Bone Disease.

    Reference Module in Biomedical Sciences. 2019 (in press)

     

  7. Oda S, Nakaura T, Utsunomiya D, Hirakawa K, Takashio S, Izumiya Y, Tsujita K, Kawano Y, Okuno Y, Hata H, Matsuoka M, Yamashita T, Ueda M, Ando Y, Yamashita Y.

    Clinical potential of dual-energy cardiac CT in cardiac amyloidosis.

     Amyloid.2019;26(sup1):91-92. doi: 10.1080/13506129.2019.1582021. PMID: 31343298

  8. Sahin I, Kawano Y, Sklavenitis-Pistofidis R, Moschetta M, Mishima Y, Manier S, Sacco A, Carrasco R, Fonseca R, Roccaro AM, Witzig T, Ghobrial IM.

    Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.

    Blood Advances.2019 Apr 9;3(7):995-1002. doi: 10.1182/bloodadvances.2018028456.  PMID: 30940634

     

  9. Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G.

    Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.

    Nat Commun.2019 Apr 10;10(1):1653. doi: 10.1038/s41467-019-09710-z. PMID: 33197296

  10. Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K J, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

    Potential role for secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.

    Oncol Rep.2019 Dec;42(6):2836-2843. doi: 10.3892/or.2019.7339. Epub 2019 Sep 27. PMID: 31578586

  11. Iriyama N, Tokuhira M, Sato E, Sugimoto K J, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

    Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.

    Hematol Oncol . 2019 Aug;37(3):323-325.doi: 10.1002/hon.2617. Epub 2019 Apr 26. PMID: 30950076

  12. Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

    Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

    Int J Hematol .2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. PMID: 31538327

  13. Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T.

    New Target investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

    Int J Hematol .2019 Apr;109(4):426-439.  doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb14.PMID: 30762219

  14. Matsumura T, Nakamura-Ishizu A, Takaoka K, Maki H, Muddineni SSNA, Wang CQ, Suzushima H, Kawakita M, Asou N, Matsuoka M, Kurokawa M, Osato M, and Suda T.

    TUBB1 dysfunction in inherited thrombocytopenia causes genome instability.

     Br J Haematol. 2019 Jun;185(5):888-902. doi: 10.1111/bjh.15835. Epub 2019 Mar 10.

     

  15. Noyori O, Komohara Y, Nasser H, Hiyoshi M, Ma C, Pan C, Carreras J, Nakamura N, Sato A, Ando K, Okuno Y, Nosaka K, Matsuoka M, and Suzu S.

    Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.

    Clin Transl Immunology.2019 Aug 13;8(8):e1074. doi: 10.1002/cti2.1074. eCollection 2019. PMID: 31417675

  16. Alam MM, Kuwata T, Tanaka K, Alam M, Takahama S, Shimura K, Matsuoka M, Fukuda N, Morioka H, Tamamura H, and Matsushita S.

    Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors.

    Biochem Biophys Rep 20:100687,

  17. Bangham CRM, Miura M, Kulkarni A, and Matsuoka M.

    Regulation of Latency in the Human T Cell Leukemia Virus, HTLV-1.

    Annu Rev Virol 6:365-385, 2019.

  18. Ma G, Yasunaga JI, Ohshima K, Matsumoto T, and Matsuoka M.

    Pentosan polysulfate demonstrates anti-HTLV-1 activities in vitro and in vivo.

    J Virol 93:e00413-19, 2019.

  19. Cui G, Shimba A, Ma G, Takahara K, Tani-Ichi S, Zhu Y, Asahi T, Abe A, Miyachi H, Kitano S, Hara T, Yasunaga JI, Suwanai H, Yamada H, Matsuoka M, Ueki K, Yoshikai Y, Ikuta K.

    IL-7R-Dependent Phosphatidylinositol 3-Kinase Competes with the STAT5 Signal to Modulate T Cell Development and Homeostasis.

    J Immunol. 2020 Feb 15;204(4):844-857. doi: 10.4049/jimmunol.1900456. Epub 2020 Jan 10.

  20. Maeda M, Tanabe-Shibuya J, Miyazato P, Masutani H, Yasunaga JI, Usami K, Shimizu A, Matsuoka M.

    IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia.

    Front Microbiol. 2020 Mar 6;11:356. doi: 10.3389/fmicb.2020.00356. eCollection 2020.

  21. Izaki M, Yasunaga JI, Nosaka K, Sugata K, Utsunomiya H, Suehiro Y, Shichijo T, Yamada A, Sugawara Y, Hibi T, Inomata Y, Akari H, Melamed A, Bangham C, Matsuoka M.

    In vivo dynamics and adaptation of HTV-1-infected clones under different clinical conditions

    PLOS Pathogens.2021 Feb 1;17(2):e1009271. doi: 10.1371/journal.ppat.1009271. Online ahead of print .PMID: 33524072

     

  22. Kimura Y, Iwanaga E, Iwanaga K, Endo S, Inoue Y, Tokunaga K, Nagahata Y, Masuda K, Kawamoto H, Matsuoka M.

    A regulatory element in the 3′-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia.

    Eur J Haematol. 2020 Nov 16.doi:10.1111/ejh.13551. PMID:33197296

     

  23. Higuchi Y, Yasunaga JI, Mitagami Y, Tsukamoto H, Nakashima K, Ohshima K, Matsuoka M. HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling.

    Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13740-13749. doi: 10.1073/pnas.1922884117. Epub 2020 May 29. PMID: 32471947; PMCID: PMC7306771.

  24. Ghosh AK, Kovela S, Osswald HL, Amano M, Aoki M, Agniswamy J, Wang YF, Weber IT, Mitsuya H.
    Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    J Med Chem. 2020 May 14;63(9):4867-4879. doi: 10.1021/acs.jmedchem.0c00202. PMID: 32348139; PMCID: PMC7425579

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.